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Adherence to a Mediterranean diet and Alzheimer’s
disease risk in an Australian population
S Gardener1,2, Y Gu3,4, SR Rainey-Smith1,2, JB Keogh5, PM Clifton6,7, SL Mathieson2, K Taddei1,2, A Mondal1,2,
VK Ward1,2, N Scarmeas3,4,8, M Barnes9, KA Ellis10,11,12, R Head9, CL Masters10,13, D Ames11,12, SL Macaulay14,
CC Rowe15, C Szoeke14 and RN Martins1,2, for the AIBL Research Group16
The Mediterranean diet (MeDi), due to its correlation with a low morbidity and mortality for many chronic diseases, has
been widely recognised as a healthy eating model. We aimed to investigate, in a cross-sectional study, the association
between adherence to a MeDi and risk for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in a large, elderly,
Australian cohort. Subjects in the Australian Imaging, Biomarkers and Lifestyle Study of Ageing cohort (723 healthy controls
(HC), 98 MCI and 149 AD participants) completed the Cancer Council of Victoria Food Frequency Questionnaire. Adherence to the
MeDi (0- to 9-point scale with higher scores indicating higher adherence) was the main predictor of AD and MCI status
in multinominal logistic regression models that were adjusted for cohort age, sex, country of birth, education, apolipoprotein
E genotype, total caloric intake, current smoking status, body mass index, history of diabetes, hypertension, angina, heart attack
and stroke. There was a significant difference in adherence to the MeDi between HC and AD subjects (Po0.001), and in
adherence between HC and MCI subjects (Po0.05). MeDi is associated with change in Mini-Mental State Examination score over
an 18-month time period (Po0.05) in HCs. We conclude that in this Australian cohort, AD and MCI participants had a lower
adherence to the MeDi than HC participants.
Translational Psychiatry (2012) 2, e164; doi:10.1038/tp.2012.91; published online 2 October 2012
Introduction
Current literature regarding the impact of individual nutrients
or food items on Alzheimer’s disease (AD) risk is inconsistent,
partly because humans eat meals with complex combinations
of nutrients or food items that are likely to be synergistic,
thereby creating complications when determining which of the
dietary components are exerting a protective or adverse
effect. In the case of antioxidants, for example, there is
evidence in cardiovascular disease literature showing that
cofactors found in whole foods are required for some
antioxidants to be fully effective. Furthermore, the magnitude
of effect of single antioxidants may not be sufficient for a
clinical impact to be observed.1 As an alternative approach,
dietary pattern analysis has emerged, one of these dietary
patterns is the Mediterranean diet (MeDi).
The MeDi has received much attention for its role in the
prevention of AD. The MeDi is characterised by a high intake
of vegetables, legumes, fruits, cereals, fish and unsaturated
fatty acids (mostly in the form of olive oil), low intake of
saturated fatty acids, meat and poultry, low-to-moderate
intake of dairy products (mostly cheese and yoghurt) and a
regular but moderate amount of alcohol (mostly wine and
generally with meals). This diet includes many dietary
components reported to be beneficial in reducing AD risk.2
For example, many vegetables, fruits, legumes and cereals
contain antioxidants, which combat oxidative stress. Previous
studies in New York and Chicago have found that higher
adherence to the MeDi was associated with lower AD risk.3,4 A
study in France found that the MeDi may reduce the rate of
cognitive decline in the elderly.5 Currently, there are no
studies replicating and confirming these findings in an
Australian population.
Higher adherence to a MeDi has been associated with
lower risk for dyslipidemia,6,7 hypertension,6–9 abnormal
glucose metabolism7,8 and coronary heart disease7,10–12—
all thought to increase AD risk. Furthermore, greater
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adherence to a MeDi has been associated with lower levels of
cerebrovascular disease, which is also considered a risk
factor for AD.13
The current cross-sectional analysis was designed to
investigate the association between adherence to the MeDi
and AD risk in a large, elderly, Australian cohort. The results
could then be compared with previous findings in the North
American and French populations.
Materials and methods
Samples and procedures. The Australian Imaging, Bio-
markers and Lifestyle Study of Ageing (AIBL) study14 is a
longitudinal study of 1112 volunteers including healthy
control (HC), mild cognitive impairment (MCI) and AD
individuals who are being assessed for prospective research
into ageing and AD. The cohort comprised 768 HC, 133 MCI
and 211 AD individuals at baseline. All AIBL volunteers were
aged 60 years and above at baseline, and excluded if they
had a history of non-AD dementia, schizophrenia, bipolar
disorder, significant current depression, Parkinson’s disease,
cancer (other than basal cell skin carcinoma) within the last 2
years, symptomatic stroke, insulin-dependent diabetes,
uncontrolled diabetes mellitus or current regular alcohol
use exceeding two standard drinks per day for women or four
per day for men. During clinical review panels, a consensus
diagnosis was assigned for each participant, which included
consideration of diagnostic criteria (DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition)
diagnosis15 and International Classification of Disease
(ICD)-10 diagnosis16). Where appropriate, ICD-10 dementia
severity rating,16 NINCDS-ADRDA AD diagnosis (probable
or possible) and MCI classifications were applied. The
clinical review panel comprised old age psychiatrists, a
neurologist, a geriatrician and neuropsychologists. MCI
diagnoses were made according to the protocol based upon
the criteria of Winblad et al.,17 which are informed by the
criteria of Petersen et al.18 Consistent with Winblad criteria,
all participants classified with MCI had either personally, or
through an informant, reported memory difficulties.17 Sub-
jects were given written instructions of the risks and benefits
of their participation in the study, and signed informed
consent was obtained before data collection commenced.
The AIBL study was approved by the Institutional Ethics
Committees of the Austin Health, St Vincent’s Health,
Hollywood Private Hospital and Edith Cowan University.14
18-Month follow-up assessment. Of the 723 HCs who
completed the Cancer Council of Victoria Food Frequency
Questionnaire (CCVFFQ) at baseline, 664 returned for follow-
up assessment after 18 months. The remaining 59 HC
participants either withdrew from the study between visits, or
were deceased at the time of their follow-up appointment. In
all, 12 participants were excluded from the analysis due to
incomplete neuropsychological test results, leaving a total of
652 HCs in the analysis. The follow-up assessment included a
neuropsychological test battery, which had also been com-
pleted at baseline assessment, enabling generation of
repeated cognitive performance data. For the purpose of the
analysis, the results from the following four neuropsychological
tests were used; the Mini-Mental State Examination, Logical
Memory II (WMS; Story 1 only), California Verbal Learning
Test II—Second Edition (long delay) and Delis-Kaplan
Executive Function System Verbal Fluency.
Genotyping. Fasting blood samples were obtained using
standard venipuncture of the antecubital vein and collected
into EDTA tubes containing prostaglandin E1 (Sapphire
Biosciences, Sydney, NSW, Australia, 33  3 ng ml 1) to
prevent platelet activation. Whole blood was stored at
 801C in 200 ml aliquots, thawed then centrifuged to
separate leucocytes when required. DNA was isolated from
the leucocytes, using the Qiagen Midiprep kits (Hilden,
Germany), and apolipoprotein E (APOE) genotype was
determined using PCR amplification and restriction enzyme
digest techniques.19
Evaluation
Diet. Of the baseline cohort, 723 HC, 98 MCI and 149 AD
subjects completed the CCVFFQ. The 74-item self-adminis-
tered semi-quantitative FFQ assesses usual daily food intake
over the preceding 12 months. The CCVFFQ has previously
been validated relative to 7-day weighed food records.20 The
responses were analysed by the Cancer Council in Carlton,
Victoria, Australia. The food composition data used to
calculate daily nutrient intake originates from the Nutrient
Tables for use in Australia 1995 (NUTTAB95).
The HCs in the AIBL cohort completed the CCVFFQ
themselves. The MCI subjects had cognitive dysfunction,
which did not significantly restrict the performance of activities
of daily living; therefore they were also able to complete the
CCVFFQ without requiring assistance. The majority of AD
participants in the AIBL study who completed the CCVFFQ at
baseline were early stage, mild AD; most were living at home
with carers, normally a spouse or family member. The AD
participant completed the CCVFFQ with assistance from the
carer; alternatively, the carer validated the completed ques-
tionnaire afterwards. In each case, the carer lived with the AD
participant, so either prepared the meals for them or was
aware of meals they consumed.
We followed the most commonly described method to
construct the MeDi score.10 An individual was assigned a
value of 1 for each; beneficial component (fruits, vegetables,
legumes, cereals and fish) if his/her caloric-adjusted con-
sumption was at or above the gender-specific median; for
each detrimental component (meat and dairy products) where
caloric-adjusted consumption was below the gender-specific
median; and for a ratio of monounsaturated fats to saturated
fats at or above the median. Individuals were also assigned a
value of 1 for mild to moderate alcohol consumption (45 to
o25 g per day for females and 410 to o50 g per day for
males). The MeDi score was generated for each participant by
adding the scores for each category. Thus, the MeDi score
could range from 0 to 9, with a higher score indicating a
greater adherence to the MeDi.21
Covariates. Analyses were adjusted for age (years), educa-
tion (p 12 and 412 years), current smoking status, body
mass index (BMI; calculated as weight in kilograms divided
by height in metres squared) and total energy intake (kcal).
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Country of birth was used as a dichotomous variable
(Australian or other). APOE genotype was also used
dichotomously: the absence of e4 allele vs presence of either
one or two e4 alleles. A history of diabetes, hypertension,
angina, heart attack and stroke were defined by self-report.
Missing variable data. The only variable with missing data
was BMI. We used multivariate imputation by chain equation
to provide BMI values for 102 participants. It was observed
that the distribution of the imputed BMI data was comparable
to that of the initial BMI data, thus we deemed the imputed
BMI values to be acceptable for inclusion in the subsequent
analysis.
Statistical analyses. All statistical analyses were con-
ducted using the R Statistical Software (version 2.12.2; the
R Foundation for Statistical Computing, Vienna, Austria),
except the 18-month follow-up assessment analysis, which
was conducted using the statistical package for the social
sciences (SPSS, Chicago, IL, USA) version 19.
Multinomial logistic regression analyses. Data were
distributed across three groups, HC, MCI and AD. All
categorical predictors were used as factors. HC was the
reference category.
Basic model. We calculated multinomial logistic regression
models with diagnosis at baseline evaluation as the outcome:
HC vs AD or MCI. The main predictor was the baseline visit
MeDi score as an ordinal score.
Adjusted model. Owing to demographic and clinical differ-
ences between the three classification groups, in subsequent
models we simultaneously adjusted for the following: age at
assessment, sex, country of birth, education, APOE e4
allele status, current smoking status and BMI. Although
caloric intake adjusted residuals were used in the MeDi
score calculation, we also included caloric intake as a
covariate in the models (as recommended by Willet and
Stampfer22).
Fully adjusted model with vascular comorbidities. We
simultaneously included all vascular risk factors (history of
stroke, diabetes, hypertension, angina and heart attack) in
the fully adjusted logistic regression model.
Using raw scores from the neuropsychological tests, a l
score was generated for each participant indicating change in
each neuropsychological test result between the baseline and
18-month follow-up assessment. A partial correlation was
performed individually for each set of l scores for each of the
four neuropsychological tests, adjusted for the covariates
listed previously.
Results
Compared with HC subjects, subjects with AD had a lower
mean MeDi score (Po0.001); and compared with HC
subjects, subjects with MCI had a lower mean MeDi score
(Po0.05; Table 1 and Figure 1). MCI compared with AD lacks
statistical significance.
Higher adherence to the MeDi was seen in HCs relative to
AD subjects. The results were similar in both adjusted and
unadjusted models (Table 2). The P-values, as shown in
Table 2, indicate that the overall effect of the MeDi is
statistically significant.
Compared with the reference HC category, each additional
unit in the MeDi score was associated with 13–19% lower
Table 1 Demographic, clinical and dietary characteristics for subjects with AD, MCI and HC
Characteristics All (n¼970) AD (n¼149) MCI (n¼98) HC (n¼723) P-valuea
Age, years; mean (s.d.) 71.72 (7.86) 77.50 (8.20) 76.01 (7.78) 69.94 (6.95) 0.000
Gender, men; no. (%) 407 (42) 63 (42) 41 (42) 303 (42) 0.996
Educationr12 years; no. (%) 477 (49) 89 (60) 53 (54) 335 (46) 0.007
MMSE; mean (s.d.) 27.07 (4.34) 19.10 (5.22) 26.16 (2.70) 28.86 (1.19) 0.000
Presence of APOE e4 allele; no. (%) 331 (34) 93 (62) 52 (53) 186 (26) 0.000
Energy intake, Kcal; mean (s.d.) 1695 (599) 1702 (616) 1710 (618) 1691 (594) 0.942
BMI; mean (s.d.)b 26.16 (4.23) 24.80 (4.34) 25.56 (3.75) 26.45 (4.22) 0.000
Smoking; no. (%)
Past 444 (46) 74 (50) 51 (52) 319 (44) 0.197
Current 29 (3) 0 (0) 4 (4) 25 (3) 0.063
Country of birth, Australian; no. (%) 687 (71) 105 (70) 63 (64) 519 (72) 0.308
Diabetes; no. (%)c 76 (8) 14 (9) 11 (11) 51 (7) 0.263
Hypertension; no. (%)c 387 (40) 56 (38) 39 (40) 292 (40) 0.817
Angina; no. (%)c 70 (7) 14 (9) 13 (13) 43 (6) 0.017
Heart attack; no. (%)c 50 (5) 10 (7) 7 (7) 33 (5) 0.360
Stroke; no. (%)c 33 (3) 17 (11) 2 (2) 14 (2) 0.000
MeDi; mean (s.d.) 4.40 (1.64) 3.79 (1.57) 4.02 (1.63) 4.57 (1.62) 0.000
MeDi tertiles; no. (%) 0.000
Low (0 3) 289 (30) 66 (44) 36 (37) 187 (26)
Middle (45) 428 (44) 65 (44) 44 (45) 319 (44)
High (69) 253 (26) 18 (12) 18 (18) 217 (30)
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body mass index; HC, healthy control; MCI, mild cognitive impairment; MeDi, Mediterranean
diet; MMSE, Mini-Mental State Examination.
aBold values indicate statistical significance (Po0.05); characteristics compared using analysis of variance for continuous variables and w2 for categorical variables.
bBMI is calculated as weight in kilograms divided by height in metres squared. cHistory of diabetes, hypertension, angina, heart attack or stroke.
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odds of being in the MCI category, and 19–26% lower odds of
being in the AD category.
A significant correlation (Po0.05) was observed between
baseline MeDi score and change in Mini-Mental State
Examination score between baseline and 18-month follow-up
assessment in HC participants. No significant correlation was
observed between baseline MeDi score and the other three
neuropsychological test scores in healthy individuals (Table 3).
Supplementary data shows demographic and clinical char-
acteristics by MeDi score tertile in all clinical classification
groups (Supplementary Table 1), and in HC group alone
(Supplementary Table 2).
Discussion
Our analysis suggests that lower adherence to the MeDi is
associated with MCI and AD. This is consistent with previous
studies.3–5 This is the first study on AD to use an elderly
Australian cohort to replicate findings described in US and
French populations. Australia is a geographically isolated
country with a different ethnic mix and it is interesting that our
results concur with those previously described. The US
population was taken from the Northern Manhattan area; it
comprised 2258 non-demented individuals who were
assessed at intervals of B18 months. These participants
had a mean age of 77.2 with a s.d. of 6.6 at baseline
assessment. Over the course of 4 years there were 262
incident AD cases, and the investigators concluded that
higher adherence to the MeDi was associated with lower AD
risk. The French study cohort comprised 1410 individuals
aged 65 and over; all were non-demented at baseline and
underwent a follow-up assessment within 5 years. Cognitive
performance was assessed using the outcome of four
neuropsychological tests, including Mini-Mental State Exam-
ination; the investigators concluded that each additional unit of
MeDi score was associated with fewer Mini-Mental State
Examination errors at follow-up.
The associations between MeDi and AD reported in this
study remained unchanged and significant even when
adjusted for the most commonly considered potential con-
founders for AD, such as age, sex, education, APOE
genotype, country of birth (Australia vs other), caloric intake,
BMI, current smoking status, hypertension, angina, stroke,
diabetes and heart attack.
The only other Australian study to investigate the associa-
tion between MeDi and cognitive decline was the PATH
through life study conducted in Canberra.23 This cohort
comprised 1528 cognitively normal individuals aged 60–64
years. Individuals were tested at two time points, 4 years
apart. After the follow-up assessment, 10 participants were
diagnosed with MCI, 10 participants with a clinical dementia
rating of 0.5 and 37 participants presented with any mild
cognitive disorder. The authors observed that greater
adherence to the MeDi was not protective against cognitive
impairment, though they did find that diet shares important
associations with cognitive health. The apparent lack of
protection afforded by the MeDi may be explained by the
heterogeneous nature of the study population. Furthermore,
Figure 1 Comparison of mean MeDi score using general linear model adjusted
for necessary covariates. Bars represent mean (±s.e.); general linear model
adjusted for necessary covariates; *Po0.05, ***Po0.001. Adjusted for age, sex,
education, apolipoprotein E genotype, country of birth (Australia vs other), body
mass index, total caloric intake, current smoking status and history of hypertension,
angina, stroke, diabetes and heart attack. Abbreviations: AD, Alzheimer’s disease;
HC, healthy control; MeDi, Mediterranean diet; MCI, mild cognitive impairment.
Table 2 Odds ratio of being classified as AD or MCI compared with a healthy
control classification
Model a Number of
subjects
included in
model
Classification OR 95% CI P-
value
Model 1 970 HC 1.00
(reference)
MCI 0.809 0.71–0.92 **
AD 0.740 0.66–0.83 ***
Model 2 970 HC 1.00
(reference)
MCI 0.863 0.75–1.00 *
AD 0.813 0.71–0.93 **
Model 3 970 HC 1.00
(reference)
MCI 0.866 0.75–1.00 *
AD 0.806 0.71–0.92 **
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CI, con-
fidence interval; HC, healthy control; MCI, mild cognitive impairment; OR, odds
ratio.
Multinomial logistic regression analysis; *Po0.05, **Po0.01 and ***Po0.001.
aModel 1: unadjusted. Model 2: adjusted for age at assessment, sex, country of
birth, education, APOE E4 allele status, current smoking status, caloric intake
and BMI. Model 3: adjusted for covariates in model 2 and history of stroke,
diabetes, hypertension, angina and heart attack.
Table 3 Partial correlation results showing baseline MeDi score is correlated
with change in cognitive performance in HC
l For neuropsychological test Significancea Correlation
MMSE 0.014 0.098
LM II 0.779 0.011
D-KEFS Verbal Fluency 0.294 0.042
CVLT II Long Delay 0.472 0.029
Abbreviations: CVLT II, California Verbal Learning Test—Second Edition;
D-KEFS, Delis-Kaplan Executive Function System; HC, healthy control; LM II,
Logical Memory II (WMS; Story 1 only); MeDi, Mediterranean diet; MMSE,
Mini-Mental State Examination.
aBold value indicates statistical significance (Po0.05); partial correlation.
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only 66 participants from the original 1528 underwent any
cognitive change in the 4 years between assessments; this
low number may have resulted in insufficient statistical power
to detect MeDi effects.
Most studies have excluded MCI individuals from their
investigations, resulting in a lack of information on factors that
may promote conversion to AD. However, consistent with our
findings, a study by Scarmeas et al.24 found a higher
adherence to the MeDi is associated with a trend of reduced
risk of developing MCI, and reduced risk of MCI conversion to
AD. Another study from the United States comprising 1640
cognitively normal and 329 MCI subjects also found a higher
MeDi score may be beneficial to cognitive function, and
observed a borderline reduced risk of MCI incidence and
conversion to dementia.25
One of the possible mechanisms through which the MeDi
may be exerting its protective effect for AD could be via effects
on the vascular system.26–28 There is strong evidence linking
the MeDi to lower incidence of vascular disease-associated
conditions such as dyslipidemia,6,7 hypertension,6–9 abnormal
glucose metabolism7,8 and coronary heart disease,7,10–12
which are also risk factors for AD. Scarmeas et al.29
investigated whether there was attenuation of the association
between MeDi and AD when vascular variables (stroke,
diabetes mellitus, hypertension, heart disease and lipid levels)
were simultaneously introduced in their logistic regression
models, which used diagnosis at baseline evaluation as the
dichotomous outcome and MeDi score as the main predictor.
They noted that their association with the MeDi and AD is not
mediated by vascular comorbidities, concluding it could be the
result of other biological pathways or measurement error in the
vascular variables. Scarmeas et al.13 also demonstrated an
association between the MeDi and cerebrovascular disease,
specifically magnetic resonance imaging infarcts: subjects in
the highest tertile of MeDi adherence had a reduction in odds
for brain infarcts of about 40%. This study also found that
among cardiovascular risk factors, only hypertension was
associated with brain infarcts in adjusted models.
Oxidative stress could be another biological mechanism
linking the MeDi and AD. AD brains exhibit constant evidence
of reactive oxygen species and reactive nitrogen species-
mediated injury. These reactive species, formed during normal
metabolic processes, are generally unstable and highly
reactive; for this reason their levels are normally kept low by
efficient antioxidant systems. In some circumstances, their
production can exceed the antioxidant ability to destroy them,
and oxidative stress occurs.30 Increasing the intake of antio-
xidants should theoretically counteract the detrimental effects
of oxidative stress and thereby reduce AD risk. Complex
phenols and many other substances with important antioxidant
properties, such as olive oil,31 wine, fruits and vegetables,
vitamins C, E, B12, folate and carotenoids,32–37 are found in
high concentrations in the typical components of the MeDi,38
and may reduce markers of oxidative stress. The MeDi could
be capturing the composite influence of dietary antioxidants
and this could, at least partially, provide an explanation for the
observed association with a lower risk of AD.
The protective role of the MeDi against cognitive decline
may also be mediated by attenuation of the inflammation
pathway. Inflammation has been found to be associated with a
higher risk for AD and cognitive decline. Higher adherence to
the MeDi has been associated with lower C-reactive protein
levels (an inflammatory marker that has been detected in
neuritic plaques and neurofibrillary tangles in the brains of
patients with AD and is upregulated in AD brains and serum),
in both observational6,39,40 and interventional studies.8,41
However, a prospective study by Gu et al.21 concluded
that the favourable association between better adherence to
the MeDi and lower risk of AD did not seem to be mediated
by high-sensitivity C-reactive protein, fasting insulin or
adiponectin (an adipokine, with low levels linked to metabolic
syndrome and inflammation). High-sensitivity C-reactive
protein was used as an index of systemic inflammation, and
fasting insulin and adiponectin as indices of metabolic
profile. The authors suggested that other aspects of
inflammatory and metabolic pathways not captured by these
biomarkers may be relevant to the MeDi-AD association, for
example, interleukin-6.21
Our study was conducted in an Australian cohort, which is
unlikely to adhere strictly to a diet typical of Mediterranean
countries. Therefore, ‘true MeDi’ adherence in our population
may be significantly lower when compared with Mediterra-
nean populations, and subjects with high MeDi adherence in
Australia may be potentially categorised as low MeDi adhe-
rence subjects compared with Mediterranean populations.
However, our results support the notion that the beneficial
effects of the MeDi are transferable to different populations.
There are limitations to our report; this is a cross-sectional
study, so we cannot assume that our results show decreased
adherence to the MeDi is a risk factor for AD, only that in our
cohort the AD participants had a decreased adherence to the
MeDi at baseline. This could be explained by a change in
dietary patterns owing to AD diagnosis. In addition, we
recognise that other factors may counteract the beneficial
effects of the MeDi, for example, participants with a MeDi
score of 8 who nevertheless develop AD could be explained
by their current smoking status, APOE genotype or other
factors. It should be noted that the vast majority of our cohort
are Caucasians and inferences regarding similar effects in
other populations may therefore be limited.
Within the AIBL study we do not collect data pertaining to
family origin, although we acknowledge the influence family
origin will have on the participant’s current dietary habits. It has
long been recognised that cultural factors are dominant in food
selection. Cultural influences lead to differences in the habitual
consumption of certain foods and in traditions of preparation,
and in certain cases can lead to restrictions such as exclusion of
meat and milk from the diet.42 There is a dynamic influence of
culture on many aspects of family lifestyle across generations.
The daily practices of eating are an accumulation of
exposures—not just familial and intergenerational but also
social and environmental.43 Adult dietary habits are determined
by familial and cultural factors rooted in childhood and
adolescence,44 and family members show similarities in food
preferences. 45 In a study by Green et al.43 there was evidence
of influences on eating across the span of three generations.
Not only did culture influence what was included as part of daily
life but also what was prohibited. A range of dietary restrictions
were reported to varying degrees. Where restrictions such as
vegetarianism or the prohibition of pork were imposed, the
Mediterranean diet and Alzheimer’s disease
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restrictions were readily accepted and were attributed to family
or social tradition or religion. Fasting was perceived as a way of
retaining the traditions of a culture and setting examples
for children to follow. Patterns of global migration mean that
large numbers of people have moved to western nations,
influencing the dietary habits and lifestyle of many migrants.
There is a wider variation in diet as a result of this migration.
With dietary habits and lifestyle undergoing transition as a result
of migration, cultural background is now relevant to many
diseases.43 However, a number of studies have shown that
where individuals have migrated from one country to another,
they have developed conditions commonly seen in the country
they emigrate to, for example, increased incidence of cardio-
vascular disease and cancer in US residents born overseas.46
The FFQ utilised in this study relied on participants’
estimations of food intake over the previous 12-month period;
this is a common limitation of studies of diet and disease and
can lead to misclassification of exposure due to limited
accuracy, and therefore misclassification of MeDi adherence.
This is particularly important where the AD participants are
concerned; we are relying on the carers for validation or
assistance with completion of the CCVFFQ, and therefore
assuming the carers are cognitively intact themselves, which
may not be the case due to a large proportion of the carers
being elderly spouses. Misclassification of diet is also not
equal between persons with and without cognitive impair-
ment, there is higher misclassification in MCIs than HCs, and
this raises the potential for ‘differential’ misclassification bias.
One option to address this limitation, which we will utilise in our
subsequent longitudinal analysis, is to follow HCs that convert
to MCI or AD between baseline and subsequent follow-ups.
However, by excluding the ADs and MCIs in the cohort and
analysing change in neuropsychological test scores over an
18-month period, we show that diet is not confounded by cogni-
tive performance. Based on these analyses it seems more likely
that we can rely on the CCVFFQ data for MCIs and ADs and that
dietary change due to an AD or MCI diagnosis is not an issue.
The CCVFFQ is known to under-report certain foods,
including soft drinks and snack foods. Moreover, the
differences in the FFQ completion protocol for each cogni-
tively intact, MCI and AD participant leads to even more ‘noise’
in the diet data, and we recognise that ideally a nutrient
biomarker pattern that reflects the MeDi diet would be used as
an approach for circumventing the limitations of using the FFQ
in MCI and AD individuals. The MeDi score itself also has
limitations; it weighs equally the underlying individual food
categories, which in turn are composed of different numbers
of food constituents. Frequencies of food intake are based on
relatively few diet constituents, which may underestimate the
overall quantity of food in each food category.
Despite the use of standard criteria, the diagnostic exper-
tise of the AIBL group and the thorough workup, there is always
the possibility of disease misclassification. It is also possible
that diet is related to socioeconomic status or to other habits or
characteristics related to better health and a lower risk for AD.
We addressed this by adjusting for country of birth (Australia vs
other), years of education, current smoking status, BMI, history
of hypertension, angina, stroke, diabetes and heart attack.
Another confounder usually considered in nutritional epidemiol-
ogy is caloric intake. We used caloric intake adjusted residuals
for MeDi score calculation and also included caloric intake as a
covariate (as Willet and Stampfer recommended).22 However,
we found that ADs and MCIs had a lower adherence to the MeDi
even after analysis with caloric intake as a covariate.
Many additional aspects of our study provide confidence in
our findings. The dietary data were collected using an
instrument previously validated in earlier epidemiological
studies. We used an a priori developed dietary pattern.10
Measures for multiple potential risk factors have been
recorded carefully and adjusted for in the analyses.
In summary, the findings of our study are similar to those
reported in French and US populations. In the Australian AIBL
cohort, both MCI and AD patients have a lower adherence to
the MeDi compared with HCs. We intend to investigate the
association between MeDi and conversion rates from HC to
MCI and AD in longitudinal analyses.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements. Samantha Gardener is supported by a University
Postgraduate Award from the Dementia Collaborative Research Centres
programme. Nikolaos Scarmeas is supported by a grant from the National Institute
on Ageing, RO1 AG028506. Funding for the AIBL study is provided by the CSIRO
Flagship Collaboration Fund and the Science and Industry Endowment Fund in
partnership with Edith Cowan University, Mental Health Research Institute,
Alzheimer’s Australia, National Ageing Research Institute, Austin Health, CogState,
Hollywood Private Hospital, Sir Charles Gardner Hospital. The study also receives
funding from the National Health and Medical Research Council, the Dementia
Collaborative Research Centres program, The McCusker Alzheimer’s Research
Foundation and Operational Infrastructure Support from the Government of Victoria.
The AIBL team thank the participants in the AIBL study for their commitment and
dedication to helping advance research into the early detection and causation of AD
and the clinicians who referred patients to the study.
Disclaimer. This study is industry sponsored. No funding source had a role in
the preparation of this article or the decision to submit the paper for publication.
1. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights.
Circulation 2011; 123: 2870–2891.
2. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer
disease mortality. Neurology 2007; 69: 1084–1093.
3. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for
Alzheimer’s disease. Ann Neurol 2006; 59: 912–921.
4. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF et al. Adherence to a
Mediterranean diet, cognitive decline, and risk of dementia. JAMA 2009; 302: 638–648.
5. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a
Mediterranean-type dietary pattern and cognitive decline in a community population.
Am J Clin Nutr 2011; 93: 601–607.
6. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the
Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The
ATTICA Study. J Am Coll Cardiol 2004; 44: 152–158.
7. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS et al. Effect of an Indo-
Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-
Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 2002; 360: 1455–1461.
8. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G et al. Effect of a
mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation
in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440–1446.
9. Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A.
Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European
Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 2004; 80:
1012–1018.
10. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet
and survival in a Greek population. N Engl J Med 2003; 348: 2599–2608.
11. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet,
traditional risk factors, and the rate of cardiovascular complications after myocardial
infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779–785.
Mediterranean diet and Alzheimer’s disease
S Gardener et al
6
Translational Psychiatry
12. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A et al.
Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and
women: the HALE project. JAMA 2004; 292: 1433–1439.
13. Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, Decarli C et al. Mediterranean diet and
magnetic resonance imaging-assessed cerebrovascular disease. Ann Neurol 2011; 69:
257–268.
14. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics
of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int
Psychogeriatr 2009; 21: 672–687.
15. Association AP Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (ed.
American Psychiatric Association: Washington, DC, 1994.
16. Organisation WHThe ICD-10 Classification of Mental and Behavioural Disorders.
Clinical Descriptions and Diagnostic Guidelines. World Health Organisation: Geneva,
1992.
17. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO et al. Mild cognitive
impairment–beyond controversies, towards a consensus: report of the International
Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240–246.
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive
impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–308.
19. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene
amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–548.
20. Ireland PJ, Giles D, O’Dea G, Powles K, Rutishauser J, Wahlqvist I et al. Development of
the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective
study involving an ethnically diverse cohort. Asia Pac J Clin Nutr 1994; 3: 19–31.
21. Gu Y, Luchsinger JA, Stern Y, Scarmeas N. Mediterranean diet, inflammatory and metabolic
biomarkers, and risk of Alzheimer’s disease. J Alzheimers Dis 2010; 22: 483–492.
22. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses.
Am J Epidemiol 1986; 124: 17–27.
23. Cherbuin N, Anstey KJ. The mediterranean diet is not related to cognitive change in a
large prospective investigation: the path Through Life Study. Am J Geriatr Psychiatry 2011;
Sep: 20.
24. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet
and mild cognitive impairment. Arch Neurol 2009; 66: 216–225.
25. Roberts RO, Geda YE, Cerhan JR, Knopman DS, Cha RH, Christianson TJ et al.
Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment.
Dement Geriatr Cogn Disord 2010; 29: 413–423.
26. Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective.
Neurobiol Aging 2000; 21: 153–160.
27. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer’s disease.
Curr Atheroscler Rep 2004; 6: 261–266.
28. Cummings JL. Alzheimer’s disease. N Engl J Med 2004; 351: 56–67.
29. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease,
and vascular mediation. Arch Neurol 2006; 63: 1709–1717.
30. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate
dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J Neurochem
1986; 46: 1042–1045.
31. Fito M, Cladellas M, de la Torre R, Marti J, Alcantara M, Pujadas-Bastardes M et al.
Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a
randomized, crossover, controlled, clinical trial. Atherosclerosis 2005; 181: 149–158.
32. Szeto YT, Tomlinson B, Benzie IF. Total antioxidant and ascorbic acid content of fresh fruits and
vegetables: implications for dietary planning and food preservation. Br J Nutr 2002; 87: 55–59.
33. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE et al. The effect of
fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 2001; 134:
1106–1114.
34. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793–795.
35. Byers T, Perry G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in
human cancers. Annu Rev Nutr 1992; 12: 139–159.
36. Owen RW, Haubner R, Wurtele G, Hull E, Spiegelhalder B, Bartsch H. Olives and olive oil
in cancer prevention. Eur J Cancer Prev 2004; 13: 319–326.
37. Stupans I, Kirlich A, Tuck KL, Hayball PJ. Comparison of radical scavenging effect,
inhibition of microsomal oxygen free radical generation, and serum lipoprotein oxidation of
several natural antioxidants. J Agric Food Chem 2002; 50: 2464–2469.
38. Mancini M, Parfitt VJ, Rubba P. Antioxidants in the Mediterranean diet. Can J Cardiol 1995;
11(Suppl G): 105G–109GG.
39. Paschos GK, Rallidis LS, Liakos GK, Panagiotakos D, Anastasiadis G, Votteas V et al.
Background diet influences the anti-inflammatory effect of alpha-linolenic acid in
dyslipidaemic subjects. Br J Nutr 2004; 92: 649–655.
40. Fung TT, McCullough ML, Newby PK, Manson JE, Meigs JB, Rifai N et al. Diet-quality
scores and plasma concentrations of markers of inflammation and endothelial dysfunction.
Am J Clin Nutr 2005; 82: 163–173.
41. Blum S, Aviram M, Ben-Amotz A, Levy Y. Effect of a Mediterranean meal on postprandial
carotenoids, paraoxonase activity and C-reactive protein levels. Ann Nutr Metab 2006; 50:
20–24.
42. Steptoe A, Pollard TM, Wardle J. Development of a measure of the motives underlying the
selection of food: the food choice questionnaire. Appetite 1995; 25: 267–284.
43. Green J, Waters E, Haikerwal A, O’Neill C, Raman S, Booth ML et al. Social, cultural and
environmental influences on child activity and eating in Australian migrant communities.
Child Care Health Dev 2003; 29: 441–448.
44. Paulus D, Saint-Remy A, Jeanjean M. Dietary habits during adolescence—results of the
Belgian Adolux Study. Eur J Clin Nutr 2001; 55: 130–136.
45. Stafleu A, Van Staveren WA, de Graaf C, Burema J, Hautvast JG. Family resemblance in
energy, fat, and cholesterol intake: a study among three generations of women. Prev Med
1994; 23: 474–480.
46. Cunningham SARJ, Venkat Narayan KM. Health of foreign-born people in the United
States: a review. Health Place 2008; 14: 623–635.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-NonCommercial-No
Derivative Works 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Mediterranean diet and Alzheimer’s disease
S Gardener et al
7
Translational Psychiatry
